Agios Pharmaceuticals, Inc. (AGIO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$37.00-0.51%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Agios Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	59.69M
EPS	—	-1.135
Annual ending 2026-12-31
Revenue	—	176.71M
EPS	—	-5.764
Annual ending 2027-12-31
Revenue	—	345.35M
EPS	—	-3.765

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve over $1 billion in peak global sales	Revenue is expected to grow from about $54 million in 2026 to over $1 billion peak sales.	Improving	no progress toward $1 billion peak sales over next 3 years	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful launch and adoption of AQVESME	A primary condition in Agios Pharmaceuticals, Inc.'s published investment case. The stated target is AQVESME launch proceeds without major setbacks.	Improving	FDA or market issues delay or limit AQVESME launch	Qualitative: FDA priority review granted (Jul 2026) FDA granted priority review to mitapivat in July 2026, a strong positive signal for the upcoming launch. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improving EPS trend toward break-even	A supporting condition in Agios Pharmaceuticals, Inc.'s published investment case. The stated target is EPS loss narrowing from -6.18 in FY26 to less negative in FY27.	Improving	EPS loss worsens or remains flat beyond FY27	Diluted EPS: $-1.69 per share FY2026-Q2; GAAP. Published target: EPS loss narrowing from -6.18 in FY26 to less negative in FY27. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026-1.69 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b3618e0e-e61b-4099-a07a-571d6b3f9fa1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches at least $54 million in 2026	A primary condition in Agios Pharmaceuticals, Inc.'s published investment case. The stated target is >=54 million USD.	Intact	revenue falls below $54 million in FY26	Revenue: $44.745M FY2026-Q2; GAAP. Published target: >=54 million USD. Target period is not explicitly aligned with this observation. Source published Jul 30, 202644,745,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b3618e0e-e61b-4099-a07a-571d6b3f9fa1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.77

$-4.65 → $-3.77 · observed estimates

FY2027 revenue$0.35B

$0.26B → $0.35B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.65	$263,221,170	10 / 10
2026-07-25	$-4.65	$263,221,170	10 / 10
2026-07-26	$-4.65	$263,221,170	10 / 10
2026-07-27	$-4.57	$262,738,068	9 / 7
2026-07-28	$-4.65	$263,221,170	10 / 10
2026-07-29	$-4.54	$270,071,170	10 / 10
2026-07-30	$-4.54	$270,071,170	10 / 10
2026-07-31	$-4.63	$275,538,240	9 / 10
2026-08-01	$-4.63	$275,538,240	9 / 10
2026-08-02	$-4.03	$329,281,660	9 / 9
2026-08-03	$-4.03	$329,281,660	9 / 9
2026-08-04	$-4.03	$329,281,660	9 / 9
2026-08-05	$-4.02	$330,153,490	10 / 10
2026-08-06	$-4.02	$330,153,490	10 / 10
2026-08-07	$-4.02	$330,153,490	10 / 10
2026-08-08	$-3.86	$339,849,070	10 / 10
2026-08-09	$-3.86	$339,849,070	10 / 10
2026-08-10	$-3.86	$339,849,070	10 / 10
2026-08-11	$-3.86	$339,849,070	10 / 10
2026-08-12	$-3.86	$339,849,070	10 / 10
2026-08-13	$-3.86	$339,849,070	10 / 10
2026-08-14	$-4.02	$330,153,490	8 / 7
2026-08-15	$-4.02	$330,153,490	8 / 7
2026-08-16	$-4.02	$330,153,490	8 / 7
2026-08-17	$-4.02	$330,153,490	8 / 7
2026-08-18	$-4.02	$330,153,490	8 / 7
2026-08-19	$-4.02	$330,153,490	8 / 7
2026-08-20	$-3.69	$351,509,070	8 / 7
2026-08-21	$-3.69	$351,509,070	8 / 7
2026-08-22	$-3.69	$351,509,070	8 / 7
2026-08-23	$-3.69	$351,509,070	8 / 7
2026-08-24	$-3.69	$351,509,070	8 / 7
2026-08-25	$-3.69	$351,509,070	8 / 7
2026-08-26	$-3.69	$351,509,070	8 / 7
2026-08-27	$-3.69	$351,509,070	8 / 7
2026-08-28	$-3.69	$351,509,070	8 / 7
2026-08-29	$-3.69	$351,509,070	9 / 7
2026-08-30	$-3.69	$351,509,070	9 / 7
2026-08-31	$-3.69	$351,509,070	9 / 7
2026-09-01	$-3.69	$351,509,070	9 / 7
2026-09-02	$-3.69	$351,509,070	9 / 7
2026-09-03	$-3.69	$351,509,070	9 / 7
2026-09-04	$-3.69	$351,509,070	9 / 7
2026-09-05	$-3.69	$351,509,070	9 / 7
2026-09-06	$-3.69	$351,509,070	9 / 7
2026-09-07	$-3.69	$351,509,070	9 / 7
2026-09-08	$-3.69	$351,509,070	9 / 7
2026-09-09	$-3.69	$351,509,070	9 / 7
2026-09-10	$-3.69	$351,509,070	9 / 7
2026-09-11	$-3.69	$351,509,070	9 / 7
2026-09-12	$-3.69	$351,509,070	9 / 7
2026-09-13	$-3.69	$351,509,070	9 / 7
2026-09-14	$-3.69	$351,509,070	9 / 7
2026-09-15	$-3.69	$351,509,070	9 / 7
2026-09-16	$-3.69	$351,509,070	9 / 7
2026-09-17	$-3.69	$351,509,070	9 / 7
2026-09-18	$-3.69	$351,509,070	9 / 7
2026-09-19	$-3.69	$351,509,070	9 / 7
2026-09-20	$-3.69	$351,509,070	9 / 7
2026-09-21	$-3.69	$351,509,070	9 / 7
2026-09-22	$-3.70	$350,936,759	9 / 7
2026-09-23	$-3.70	$350,936,759	9 / 7
2026-09-24	$-3.70	$350,936,759	9 / 7
2026-09-25	$-3.70	$350,936,759	9 / 7
2026-09-26	$-3.70	$350,936,759	9 / 7
2026-09-27	$-3.70	$350,936,759	9 / 7
2026-09-28	$-3.70	$350,936,759	9 / 7
2026-09-29	$-3.70	$350,936,759	9 / 7
2026-09-30	$-3.70	$350,936,759	9 / 7
2026-10-01	$-3.70	$350,936,759	9 / 7
2026-10-02	$-3.70	$350,936,759	9 / 7
2026-10-03	$-3.70	$350,936,759	9 / 7
2026-10-04	$-3.70	$350,936,759	9 / 7
2026-10-05	$-3.70	$350,936,759	9 / 7
2026-10-06	$-3.70	$350,936,759	9 / 7
2026-10-07	$-3.70	$350,936,759	9 / 7
2026-10-08	$-3.71	$350,936,759	8 / 7
2026-10-09	$-3.74	$348,036,759	9 / 7
2026-10-10	$-3.74	$348,036,759	9 / 7
2026-10-11	$-3.74	$347,084,782	9 / 7
2026-10-12	$-3.74	$347,084,782	9 / 7
2026-10-13	$-3.74	$347,084,782	9 / 7
2026-10-14	$-3.74	$347,084,782	9 / 7
2026-10-15	$-3.74	$347,084,782	9 / 7
2026-10-16	$-3.74	$347,084,782	9 / 7
2026-10-17	$-3.74	$347,084,782	9 / 7
2026-10-18	$-3.74	$347,084,782	9 / 7
2026-10-19	$-3.74	$347,084,782	9 / 7
2026-10-20	$-3.74	$347,084,782	9 / 7
2026-10-21	$-3.74	$347,084,782	9 / 7
2026-10-22	$-3.74	$347,084,782	9 / 7
2026-10-23	$-3.77	$345,354,782	9 / 7
2026-10-24	$-3.77	$345,354,782	9 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	3
2026-06-01	7	3
2026-07-01	7	3
2026-08-01	7	3
2026-09-01	7	3
2026-10-01	7	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Truist FinancialOct 7 · prior Jul 7

$41.00 → $37.00-9.8%

$0$22.55$45.10

0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve over $1 billion in peak global salesDirect metric needs a verified mapping
Improving EPS trend toward break-evenDiluted EPS: $-1.69 per share
Revenue reaches at least $54 million in 2026Revenue: $44.745M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-50.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Agios Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a clinical-stage biotech with an emerging commercial business, not yet a proven profitable compounder. The multi-year view is on watch: launch progress is visible, but financial performance remains below its industry cohort and the evidence snapshot gives medium confidence.

What's priced into Agios Pharmaceuticals, Inc.

AGIO trades at a sizable premium to peers, which the evidence describes as justified by a durable premium, though valuation-model confidence is low. The negative expectations gap suggests the market's embedded expectations are demanding relative to the model; the low fragility reading does not remove that execution risk.

What the fundamentals likely do

Near term, AQVESME launch momentum is encouraging: prescriptions and U.S. mitapivat revenue both rose from the first to the second quarter of 2026. AGIO remains loss-making, and research spending increased partly because of a licensing payment; recent earnings beats are positive, but performance is still below the industry cohort. The next key near-term milestone is the FDA decision on mitapivat for sickle cell disease, with a November 1, 2026 date stated in the evidence.

What Agios Pharmaceuticals, Inc. hinges on

The multi-year thesis depends on continued commercial growth in thalassemia and progress toward a potential sickle cell launch, alongside successful advancement of newer pipeline assets. A guidance cut would be a meaningful negative, while a weakening jobs report could weigh on healthcare sentiment; continued strength among sector bellwethers would support the sector backdrop.